- Price
- $4.17
- Day
- -0.71%
- Mkt Cap
- $241.49M
- 52W Range
- $2.96 – $40.37
- Volume
- 4.21M
- Beta
- 0.53
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Capricor (CAPR) To Contact Him Directly To Discuss Their Options
Read full article
NEW YORK and NEW ORLEANS, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NasdaqGS: CAPR) of a class action securities lawsuit.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 28, 2026.
Read full article
Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of inve
Read full article
New York, New York--(Newsfile Corp. - August 4, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Read full article
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Capricor Therapeutics, Inc. ("Capricor" or the “Company”) (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN CAPRICOR THERAPEUTICS, INC. (CAPR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH T.
Read full article
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming September 28, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026 inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR CAPRICOR THERAPEUTICS, INC. INVESTMENTS, CLICK HERE TO INQUIR.
Read full article
SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Capricor Therapeutics, Inc. (NASDAQ: CAPR) securities between December 17, 2025 and July 26, 2026, inclusive (the “Class Period”), have until September 28, 2026 to seek appointment as lead plaintiff of the Capicor class action lawsuit. Captioned Nkamga v.
Read full article
New York, New York--(Newsfile Corp. - August 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) on behalf of investors that purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in Capricor and have suffered losses, you may CLICK HERE to contact us.
Read full article
Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors.
Read full article
NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) between December 17, 2025 and July 6, 2026, inclusive. What To Do Next: Investors are encouraged to act promptly and submit a form at Capricor Therapeutics, Inc. Shareholder Class Action Lawsuit or contact Investor Relations Manager Peter Allocco at (212) 951-2030 or [email protected].
Read full article
Capricor Therapeutics, Inc. has been sued for securities fraud over alleged misstatements about Deramiocel and the integrity of the clinical data supporting its Biologics License Application leading to a 64% stock drop. NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and certain of the company's senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
Read full article